FDA feedback provided on potential ELI-002 Ph 3 study design, including dose, schedule, patient population and primary endpoint analysis January 28, 2025
ArsenalBio and BMS Achieve Milestone for AB-4000 Series to Advance Next-Gen T Cell Therapies for Solid Tumors January 21, 2025
A2 Biotherapeutics Closes $80 Million Series C Financing to Advance Precision Cell Therapies Using Proprietary Tmod Technology Platform January 21, 2025
Interim Data Demonstrating Safety & Confirmed Clinical Responses of ADG126 up to 10 mg/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of Ph 1b/2 Trial Announced January 11, 2025
Innovent Enters into Exclusive Global License Agreement with Roche for Novel DLL3 ADC January 7, 2025
BeiGene to acquire global development, manufacturing, and commercialization rights for an ADC from DualityBio January 7, 2025
Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia December 31, 2024
Positive Topline Results from China GC/GEJ Ph 2 Trial of Claudin18.2 CAR-T (Satri-cel) announced December 31, 2024
US FDA Approves SC Opdivo Qvantig (nivolumab & hyaluronidase-nvhy) Injection in Most Previously Approved Adult, Solid Tumor Opdivo Indications December 31, 2024
Inceptor Bio and GRIT Bio Announce Strategic Partnership to Advance IB-T101, a Next-Generation Solid Tumor CAR-T Utilizing the OUTLAST™ Platform December 26, 2024
Merck Closes Exclusive Global License Agreement for Anti-PD-1/VEGF Bispecific Antibody LM-299 December 26, 2024
Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on PYX-201 program December 26, 2024
First patient dosed in Ph 1 trial of IMC-P115C in patients with PRAME-expressing tumors December 25, 2024
Initial clinical results from ongoing KYANITE-1 study of inhaled KB707 in patients with solid tumors of the lung announced December 25, 2024
Safety Review Committee Approval of Opening 3rd Cohort and Preliminary Results from 1st Cohort in Ph 1 TTX-MC138 Trial Announced December 25, 2024
Elevation Oncology Expands Pipeline with Nomination of EO-1022 for the Treatment of HER3-expressing Solid Tumors December 18, 2024
Rondo Therapeutics Closes $67 Million Series A Financing to Advance Next-Generation Immuno-Oncology Platform for Solid Tumors December 10, 2024
Relay Therapeutics & Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors December 10, 2024
Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target December 10, 2024
